Lucid Diagnostics Inc (LUCD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) has a cash flow conversion efficiency ratio of -0.422x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.89 Million) by net assets ($25.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lucid Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Lucid Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lucid Diagnostics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Lucid Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lucid Diagnostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarana Mitra Luas
JK:SMIL
|
0.105x |
|
Den Networks Limited
NSE:DEN
|
0.015x |
|
REDELFI SPA
F:B0Z
|
N/A |
|
Empro Group Inc. Ordinary shares
NASDAQ:EMPG
|
N/A |
|
Pulse Seismic Inc
TO:PSD
|
0.076x |
|
Betmakers Technology Group Ltd
AU:BET
|
0.053x |
|
KOMPLETT ASA NK -40
F:GJ60
|
N/A |
|
Cashbil
JSE:CSB
|
0.288x |
Annual Cash Flow Conversion Efficiency for Lucid Diagnostics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Lucid Diagnostics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see LUCD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.39 Million | $-44.14 Million | -8.188x | -157.66% |
| 2023-12-31 | $-2.31 Million | $-32.82 Million | 14.200x | +1202.49% |
| 2022-12-31 | $23.05 Million | $-29.68 Million | -1.288x | -299.05% |
| 2021-12-31 | $54.74 Million | $-17.67 Million | -0.323x | -177.52% |
| 2020-12-31 | $-13.52 Million | $-5.63 Million | 0.416x | -6.38% |
| 2019-12-31 | $-5.31 Million | $-2.36 Million | 0.445x | +315.70% |
| 2018-12-31 | $-1.06 Million | $-113.70K | 0.107x | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the… Read more